As interest in psychedelics grows, the non-profit initiative titled Microdosing Collective has been launched to promote the regulated uses of psychedelics, supporting education around regulations to allow for legal, sub-perceptible microdosing for well-being purposes.
The organization believes that one potential path forward to providing access to safe psychedelics is to consider microdoses as over-the-counter wellness supplements under the scope of the FDA or a state-based system.
This new initiative points to the paradoxical fact that, while most clinical research studies work with mind-altering doses of psychedelics and existent state frameworks would allow for a high dosage as well, pathways for legal sub-perceptible doses of psychedelics currently do not exist.
That being so, the new Microdosing Collective aims at creating a legal avenue for microdosing psychedelics, yet not as a medical treatment, but as a wellness supplement.
Cofounder and drug policy attorney Joshua Kappel explained that the platform estimates “at least 600,000 people in the U.S. actively microdose psychedelic medicines.” He rightly expressed that the problem is that “none of these products are legal or guaranteed to be safe.”
On her behalf, cofounder Alli Schaper further clarified that the largest barrier to access for microdosing originates in all psychedelics’ current classification as a Schedule I drug.
Schaper is also CEO and co-founder of fungi education program "Into The Multiverse". Regarding FDA scheduling, she states that research shows that “when used correctly, with the right education and support, microdosing can have a massive positive impact on people's lives.”
“The use of these supplementation protocols is on the rise for both mental health and human optimization with thousands of people reaping the benefits. Our goal is to provide a safe and legal channel for microdosing supplements, which is really a form of harm reduction and mitigation of the risks that come from cross contamination and incorrect dosing via underground channels,” she concluded.
Photo by Zac Durant on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.